Phase 3 Daraxonrasib Trial Nearly Doubles Survival In Metastatic Pancreatic Cancer
On Sunday, May 31, 2026, Phase 3 data presented at ASCO showed the oral KRAS inhibitor daraxonrasib nearly doubled median survival in 500 patients with previously treated metastatic pancreatic cancer.[1]
Patients taking daraxonrasib had a median overall survival of 13.2 months versus 6.7 months with additional chemotherapy, and the study reported about a 60% lower risk of death.[1] Daraxonrasib recipients reported less pain, better quality of life, and stayed on treatment longer than patients assigned to chemotherapy.[1] Overall the oral drug caused fewer severe side effects than chemotherapy, but severe rash and mouth sores were the main toxicities that limited use.[1] The Food and Drug Administration plans to expedite review and has authorized an expanded-access program, and oncologists say they are being flooded with requests for the drug.[2]
Revolution Medicines developed daraxonrasib as an oral targeted therapy that blocks mutated KRAS-family proteins that drive more than 90% of pancreatic cancers.[2] Full randomized trial results were published in the New England Journal of Medicine and presented at the ASCO meeting in Chicago by Dr. Brian Wolpin.[1] Investigators and outside experts described the outcome as the first substantial survival advantage over chemotherapy in this disease and urged it become a new standard of care.[2]
Former U.S. Sen. Ben Sasse said daraxonrasib cut his tumor volume by about 76% over four months and greatly reduced his pain.[3] Oncologist Rachna Shroff said she "started crying" when she first saw the trial results.[2] The American Cancer Society estimates about 67,000 new U.S. pancreatic cancer cases and more than 52,000 deaths in 2026, with a five-year overall survival near 13%.[2]
Mainstream coverage frames the success of daraxonrasib as a breakthrough in cancer treatment, but Matthew Yglesias critiques the tendency to conflate such advancements with the broader narrative of AI curing cancer. He argues that while daraxonrasib represents significant progress, it is the result of rigorous scientific research and clinical trials, rather than a product of AI alone. This perspective highlights the importance of understanding the complexities of drug development, which the mainstream summary simplifies by focusing solely on the positive outcomes of the trial without acknowledging the broader context of ongoing research efforts and the limitations of technological solutions in medicine.
Additionally, the mainstream summary does not address the skepticism surrounding the hype often generated by new cancer treatments. Yglesias points out that media narratives can mislead the public by suggesting that recent trial results indicate a near-term solution to cancer, overshadowing the lengthy and challenging process of validating new therapies. This critical viewpoint emphasizes that while the results of the daraxonrasib trial are promising, they should be viewed within the larger framework of ongoing biomedical research rather than as evidence of a miraculous breakthrough fueled by AI or other technologies.[4]
Show source details & analysis (6 sources)
📌 Key Facts
- On Sunday, May 31, 2026, full randomized data for daraxonrasib in 500 patients with previously treated metastatic pancreatic cancer were published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting in Chicago.
- In the 500‑patient randomized trial daraxonrasib produced a median overall survival of 13.2 months versus 6.7 months with additional chemotherapy (nearly doubling survival) and was reported to reduce the risk of death by about 60%. median overall survival
- The trial enrolled patients whose metastatic pancreatic cancer had stopped responding to prior treatment; daraxonrasib recipients reported less pain, better quality of life, stayed on therapy longer, and many were still on treatment at data cutoff, a pattern trial leaders said could widen the survival gap with longer follow‑up.
- Overall the oral drug caused fewer severe side effects than chemotherapy, but the toxicities most likely to limit use were sometimes severe rash and mouth sores.
- Daraxonrasib is an oral targeted therapy developed by Revolution Medicines that blocks mutated KRAS‑family proteins that drive more than 90% of pancreatic cancers — a target that had eluded effective treatment for decades.
- The FDA plans to expedite review of daraxonrasib and has authorized an expanded‑access program, and oncologists report being “flooded with requests” as that program gets underway.
- Investigators and outside experts — including [Dr. Brian Wolpin], who presented the Phase 3 findings, and oncologist Dr. Rachna Shroff, who said she “started crying” when she first saw the results — said daraxonrasib should become a new standard of care for previously treated metastatic pancreatic cancer. https://www.pbs.org/newshour/health/experimental-drug-shows-promise-against-deadly-pancreatic-cancer
- News coverage highlighted individual response: former U.S. Sen. [Ben Sasse] reported a roughly 76% tumor reduction over four months and markedly reduced pain while taking daraxonrasib. https://www.cbsnews.com/news/pancreatic-cancer-treatment-daraxonrasib-survival-rate/
- The reporting placed the findings against U.S. disease burden from the [American Cancer Society]: an estimated 67,000 new pancreatic cancer cases and more than 52,000 deaths in 2026, with a five‑year overall survival rate near 13%. https://www.pbs.org/newshour/health/experimental-drug-shows-promise-against-deadly-pancreatic-cancer
📊 Analysis & Commentary (1)
"The piece is a skeptical commentary pushing back on headlines and hype that suggest AI will imminently 'cure cancer' — it argues real advances (like daraxonrasib) come from traditional biomedical research and trials, and that AI is a helpful tool but not a shortcut to validated cures."
📰 Source Timeline (6)
Follow how coverage of this story developed over time
- The June 1, 2026 CBS News segment reiterates that the new pancreatic cancer drug kept patients alive about twice as long as chemotherapy alone in clinical trials.
- The piece frames the key clinical distinction that the drug is an oral targeted therapy rather than traditional cytotoxic chemotherapy, emphasizing its different mechanism and side-effect profile compared with standard chemo.
- The segment is anchored by Dr. Jon LaPook, who explains for a general audience how the drug's targeted action against KRAS-driven tumors underlies the survival benefit reported at ASCO 2026.
- On June 1, 2026, CBS aired a segment in which Dr. Harsh Singh of the MGB Cancer Institute described new data showing a new drug nearly doubles survival for some pancreatic cancer patients.
- The CBS segment frames the result in lay terms as a 'nearly double rate of survival' and highlights early clinical use experience from a major U.S. cancer center.
- On Sunday, May 31, 2026, Dr. Brian Wolpin of Dana-Farber presented the daraxonrasib Phase 3 findings at the ASCO meeting and said the drug should become a new standard of care for previously treated metastatic pancreatic cancer.
- The article emphasizes that daraxonrasib targets a mutated KRAS-family protein that drives tumor growth in more than 90% of pancreatic cancer cases and notes this target had eluded treatment for decades.
- The Associated Press piece adds detailed patient and expert reaction, quoting oncologist Dr. Rachna Shroff describing how she "started crying" when she first saw the results because patients were staying on treatment with durable, meaningful benefit.
- The story reiterates that the FDA not only plans to expedite daraxonrasib’s review but has already opened an expanded-access program, with oncologists being “flooded with requests” as that program gets underway.
- It restates the median survival benefit (13.2 vs. 6.7 months) and quality-of-life advantages (less pain, fewer severe side effects such as rash and mouth sores) in the 500-patient trial, and notes many patients remained on therapy at data cutoff, suggesting the survival gap could widen.
- The article highlights U.S. disease burden figures from the American Cancer Society: an estimated 67,000 new pancreatic cancer cases and more than 52,000 deaths in the U.S. in 2026, with a five-year overall survival rate of 13%.
- CBS coverage on May 31, 2026 underscores that daraxonrasib reduced the risk of death by 60% versus additional chemotherapy in the 500-patient randomized trial of previously treated metastatic pancreatic cancer.
- The article reports that many patients were still taking daraxonrasib at the time of data cutoff, leading trial leaders to suggest the survival gap could widen with longer follow-up.
- Oncologist Dr. Rachna Shroff, not involved in the trial, described the results as so striking she "started crying" on first seeing them and highlighted that patients stayed on the drug because it provided "durable and meaningful" benefit.
- The piece reiterates that the main toxicities limiting pill use are sometimes severe rash and mouth sores but emphasizes that patients reported less pain and better quality of life than with chemotherapy.
- CBS notes former U.S. Sen. Ben Sasse, diagnosed with stage‑4 pancreatic cancer in December 2025, told "60 Minutes" in April 2026 that daraxonrasib cut his tumor volume by 76% over four months and markedly reduced his pain.
- On Sunday, May 31, 2026, full randomized data for daraxonrasib in 500 patients with previously treated metastatic pancreatic cancer were published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting in Chicago.
- Patients receiving daily daraxonrasib had a median overall survival of 13.2 months versus 6.7 months for those assigned to additional chemotherapy, nearly doubling survival time in this setting.
- The study population consisted of patients whose metastatic pancreatic cancer had stopped responding to prior treatment, and daraxonrasib recipients reported less pain, better quality of life, and stayed on therapy longer than patients on chemotherapy.
- Lead investigators and outside experts at ASCO said daraxonrasib should become a new standard of care for previously treated metastatic pancreatic cancer and called the result the first substantial survival advantage over chemotherapy in this disease.
- Side effects most likely to limit use were severe rash and mouth sores, though overall the pill caused fewer severe side effects than chemotherapy.
- The FDA plans to expedite review of daraxonrasib and has authorized an expanded-access program that allows eligible patients to receive the investigational drug while review is underway.
- The drug, developed by Revolution Medicines, targets KRAS-family mutations that drive more than 90% of pancreatic cancers, a target that had resisted effective treatment for decades.
- Former U.S. Sen. Ben Sasse has publicly discussed experiencing less pain while taking daraxonrasib, contributing to high demand for access as expanded-access programs open.